Ovid asks USPTO to review Marinus' patent around treatment of serious seizure condition
Ovid Therapeutics is ramping up its patent fight with Marinus Pharmaceuticals.
The rival biotechs have been battling for more than a year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
